Tharimmune Expands Board with New Appointments

Tharimmune, Inc., a clinical-stage biopharmaceutical company, has appointed Clay Kahler and Gary Stetz to its Board of Directors. This expansion brings the board to nine members. Kahler and Stetz will contribute extensive leadership, financial, and strategic expertise as the company advances its clinical programs and growth initiatives. The appointments come as Leonard Mazur and Lynne Bui, M.D., announced they will not seek re-election.

Kahler, co-founder of various scientific ventures, brings entrepreneurial leadership and operational expertise, while Stetz offers over 35 years of financial experience. Their diverse backgrounds are expected to support Tharimmune's strategic goals.

Kahler expressed enthusiasm for contributing to the company's innovative approaches in immune-mediated diseases. Stetz emphasized his eagerness to guide Tharimmune through its growth phase.